A Review of 2022's "Fierce 15" and What it Means for 2023

In what is becoming an annual tradition here on “The Weekly Bioanalysis” podcast, Dom and John take a bit of time to take a look back at 2022’s Fierce 15 (the annual selected list of impressively performing companies across the biotech world, highlighting a broad range of teams, leaders and science, as selected by the Fierce Biotech group). In addition to this, the guys discuss the list of drugs that received approvals throughout 2022, then they discuss the trends they see emerging from these industry lists… and what it means as we begin 2023."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, Milan, Italy, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.